Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Pipeline Insight - Substance Dependence - Part 1 - Nicotine (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 14/11/2007
- Report Title: Pipeline Insight - Substance Dependence - Part 1 - Nicotine
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 91
Introduction
The high prevalence of nicotine dependence, strong uptake of Pfizer’s Chantix (varenicline), and the launch of new innovative therapies will cause the nicotine dependence prescription drug market to grow to $4.6 billion across the seven major markets by 2016. Innovative therapies are set to offer patients a convenient dosing regimen and thereby carrying the potential for improved compliance.
Scope
Analysis of patient potential, unmet needs and clinical trial design in nicotine dependence Overview of the current nicotine dependence market, covering both prescription and OTC products Overview of drugs in late stage clinical development for nicotine dependence Profiles of key compounds in development for use in nicotine dependence, with forecasts of drug revenues to 2016 and insight from key opinion leaders
Highlights
Nicotine vaccines are the most prevalent drug class in the late-stage pipeline. This represents a move away from nicotine replacement and nicotine agonist therapies, which have historically dominated the market. The report predicts nicotine vaccine companies will be important players in the market by 2016, led by Novartis’s NIC-002. Nicotine vaccines are designed to prevent nicotine from entering the brain and thus reduce the pleasurable effect of smoking. The utility of vaccines in nicotine dependence lies in the long-term protection they provide along with minimal patient compliance and carry the potential for prophylactic use. With two compounds in late-stage development for the treatment of nicotine dependence, it is evident that Sanofi-Aventis is keen to penetrate this market. Although possessing a similar mechanism of action to Chantix, the drug’s shorter treatment course than the market leader represents a strong competitive advantage.
Reasons to Purchase
Understand unmet needs and opportunities in this market based on the comments of interviewed key opinion leaders. Benchmark key late-stage nicotine dependence compounds against the current market leader. Assess the seven major market total sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential
The high prevalence of nicotine dependence, strong uptake of Pfizer’s Chantix (varenicline), and the launch of new innovative therapies will cause the nicotine dependence prescription drug market to grow to $4.6 billion across the seven major markets by 2016. Innovative therapies are set to offer patients a convenient dosing regimen and thereby carrying the potential for improved compliance.
Scope
Analysis of patient potential, unmet needs and clinical trial design in nicotine dependence Overview of the current nicotine dependence market, covering both prescription and OTC products Overview of drugs in late stage clinical development for nicotine dependence Profiles of key compounds in development for use in nicotine dependence, with forecasts of drug revenues to 2016 and insight from key opinion leaders
Highlights
Nicotine vaccines are the most prevalent drug class in the late-stage pipeline. This represents a move away from nicotine replacement and nicotine agonist therapies, which have historically dominated the market. The report predicts nicotine vaccine companies will be important players in the market by 2016, led by Novartis’s NIC-002. Nicotine vaccines are designed to prevent nicotine from entering the brain and thus reduce the pleasurable effect of smoking. The utility of vaccines in nicotine dependence lies in the long-term protection they provide along with minimal patient compliance and carry the potential for prophylactic use. With two compounds in late-stage development for the treatment of nicotine dependence, it is evident that Sanofi-Aventis is keen to penetrate this market. Although possessing a similar mechanism of action to Chantix, the drug’s shorter treatment course than the market leader represents a strong competitive advantage.
Reasons to Purchase
Understand unmet needs and opportunities in this market based on the comments of interviewed key opinion leaders. Benchmark key late-stage nicotine dependence compounds against the current market leader. Assess the seven major market total sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
